Pre-clincal program evaluated proper formation and deposition of elastic fibers into the skin extracellular matrix in mice KB303 holds potential to be the first-ever directed approach to increase production of elastin in the skin PITTSBURGH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc.,

–  Top-line results from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) on track for 4Q21 –  Enrollment in Phase 1 proof-of-concept study (PEARL-1 study) to treat aesthetic skin conditions is complete –  Strong balance sheet with September 30, 2021 cash, cash

Topline results anticipated in the fourth quarter of 2021 Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint assessment visits PITTSBURGH , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc.

PITTSBURGH , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the presentation of pre-clinical data describing the nonclinical pharmacology of nebulized KB407, a redosable gene therapy

PITTSBURGH , Oct. 14, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment

The Krystal Decode DEB™ program is designed to shorten time to accurate diagnosis and facilitate the delivery of optimal care PITTSBURGH and GAITHERSBURG, Md. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare

PITTSBURGH , Oct. 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced its participation in the Chardan Virtual 5th Annual Genetic Medicines Conference , taking place October 4-5, 2021 .

-  KB407 is an investigational inhaled gene therapy derived from Krystal’s clinically validated redosable gene delivery technology platform PITTSBURGH , Sept. 29, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases,

PITTSBURGH , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced the appointment of Laurent Goux as the General Manager of Europe . Mr. Goux has more than 20 years of global biotechnology

Data include evaluation of investigational B-VEC in a murine corneal wound model U.S. FDA has recently approved a compassionate use request for topical B-VEC application to one eye in a RDEB patient PITTSBURGH , Sept. 09, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.